• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Biocon Ltd.
    08 Aug 2025
    359.50
    -0.73%
    Confident about Biocon's response to US tariffs: Kiran Mazumdar-Shaw
    Business Standard
    We remain confident in our global footprint and are well positioned to respond once more details are available. , said Biocon Chairperson
    Copy LinkShare onShare on Share on Share on
    Biocon Ltd. is trading above its 200 day SMA of 353.9
    Biocon's profitability to improve as structured equity exits ease interest burden: Kiran Mazumdar-Shaw
    Business Line | 08 Aug 2025
    logo
    Wockhardt Ltd.
    08 Aug 2025
    1476.90
    -0.28%
    Wockhardt's Q1 net loss widens to 108 crore
    Business Line
    Revenue in Q1 stood at 738 crore, as compared to 739 crore in the same period last year
    Copy LinkShare onShare on Share on Share on
    Promoters unpledged 2.60% of shares in last quarter. Total pledge stands at 15.64% of promoter holdings
    Wockhardt Q1 Results: Loss Widens To Rs 108 Crore
    NDTV Profit | 08 Aug 2025
    logo
    Biocon Ltd.
    07 Aug 2025
    359.50
    -0.73%
    Biocon Q1 results: Net profit down 95%, revenue rises 15% to 4,022 cr
    Business Standard
    Biocon's Q1 net profit declines sharply due to high base from one-time gain last year; biosimilars, CRDMO and generics drive revenue and operational growth
    Copy LinkShare onShare on Share on Share on
    Biocon Ltd. average weekly volume is high.
    Biocon Q1 Results: Profit Slumps 95% Even As Revenue Rises
    NDTV Profit | 07 Aug 2025
    logo
    Lupin Ltd.
    07 Aug 2025
    US FDA Observation
    2007.00
    0.13%
    Broker's call: Lupin (Buy)
    Business Line
    PL Capital
    Copy LinkShare onShare on Share on Share on
    Lupin Ltd. is trading below its 200 day SMA of 2025.1
    Lupin Q1 Review: Dolat Capital Maintains 'Add', But Cuts Target Price Here's Why
    NDTV Profit | 07 Aug 2025 3 more
    Lupin shares advance 5% after Q1 results; should you buy in?
    Business Standard | 07 Aug 2025
    Lupin Q1 Review: Goldman Sachs Remains Neutral, Hikes Target Price
    NDTV Profit | 07 Aug 2025
    As US tariffs loom, Lupin looks at measures to mitigate impact
    Business Line | 06 Aug 2025
    logo
    Emcure Pharmaceuticals Ltd.
    07 Aug 2025
    1325.00
    0.61%
    Emcure Pharmaceuticals posts 41% growth in profit in Q1
    Business Line
    International business remained a key growth driver, growing 22.1 per cent to 1,106 crore
    Copy LinkShare onShare on Share on Share on
    Emcure Pharmaceuticals Ltd. has gained 28.85% in the last 6 Months
    Emcure Pharma Q1 Results: Net Profit Up 41% At Rs 215 Crore
    NDTV Profit | 07 Aug 2025
    logo
    Lincoln Pharmaceuticals Ltd.
    07 Aug 2025
    548.00
    -0.45%
    Lincoln Pharma Q1 Results: Net Profit Rises 17%
    Lincoln Pharma Q1 Results: Net Profit Rises 17%
    NDTV Profit
    Lincoln Pharmaceuticals reported a net profit of Rs 27.7 crore for the April-June quarter.
    Copy LinkShare onShare on Share on Share on
    Lincoln Pharmaceuticals Ltd. is trading below all available SMAs
    Lincoln Pharma Q1 results: Profit up 17% to 28 cr, share jumps 8.5%
    Business Standard | 07 Aug 2025
    logo
    Hikal Ltd.
    07 Aug 2025
    260.10
    -1.07%
    Smallcap pharma stock hits 52-week low, slips 8% on Q1 loss. Do you own?
    Business Standard
    Shares of Hikal hit a 52-week low of 281.90, falling 8 per cent on the BSE in Thursday's intra-day trade after the pharma company posted a net loss of 22.4 crore in Q1FY26.
    Copy LinkShare onShare on Share on Share on
    Hikal Ltd. is trading below all available SMAs
    logo
    Alembic Pharmaceuticals Ltd.
    06 Aug 2025
    940.05
    -1.05%
    Alembic Pharma dips 3% post Q1 results; MOFSL retains Neutral, here's why
    Business Standard
    Alembic Pharma fell around 3.5 per cent to hit an intraday low of 913 on the NSE, after the company reported its June 2025 quarter results
    Copy LinkShare onShare on Share on Share on
    Alembic Pharmaceuticals Ltd. is trading below all available SMAs
    Alembic Pharma Q1 Review: Dolat Capital Maintains 'Add', Revises Target Price Here's Why
    NDTV Profit | 06 Aug 2025 1 more
    Alembic Pharma Q1 net profit rises 14% to 154 crore, revenue up 10%
    Business Standard | 05 Aug 2025
    logo
    Gland Pharma Ltd.
    06 Aug 2025
    2017.20
    0.12%
    'Buy' Gland Pharma Shares Maintains Motilal Oswal On Strong Q1 Earnings Growth, Valuation Check Target Price
    'Buy' Gland Pharma Shares Maintains Motilal Oswal On Strong Q1 Earnings Growth, Valuation Check Target Price
    NDTV Profit
    Gland Pharma is fortifying its positioning in the complex injectable space through in-house product development as well as partnerships, adds the brokerage.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 203 to 212 in Jun 2025 qtr.
    Gland Pharma shares jump 6% post Q1 show; should you buy, sell or hold?
    Business Standard | 06 Aug 2025 5 more
    Gland Pharma Share Price Surges Over 6% As Jefferies Upgrades Ratings, Hikes Target Price Post Q1 Results
    NDTV Profit | 06 Aug 2025
    Gland Pharma Q1 Review: Brokerages DividedJefferies Upgrades Rating To Hold, Citi Maintains Sell
    NDTV Profit | 06 Aug 2025
    Gland Pharma Q1 profit jumps 50% on core growth, Cenexi turnaround
    Business Standard | 05 Aug 2025
    Gland Pharma Q1FY26 net profit up 50% at 215 cr
    Business Line | 05 Aug 2025
    Gland Pharma Q1 Results: Profit Surges 50%, Meets Estimates
    NDTV Profit | 05 Aug 2025
    logo
    Eris Lifesciences Ltd.
    06 Aug 2025
    1634.90
    -0.33%
    'Buy' Eris Lifesciences Shares Maintains PL Capital Post Q1 Results; Revises Target Price
    'Buy' Eris Lifesciences Shares Maintains PL Capital Post Q1 Results; Revises Target Price
    NDTV Profit
    Eris maintains revenue growth guidance of 15-20% for FY26E, adds PL Capital
    Copy LinkShare onShare on Share on Share on
    Eris Lifesciences Ltd. is trading below its 30 day SMA of 1718.8
    Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26
    Business Standard | 05 Aug 2025
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • GK Energy
    • Siddhi Cotspin
    • Saatvik Green Energy
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd